Abstract
A phase I trial of PF-03084014, an oral reversible γ- secretase inhibitor, in solid tumor malignancies shows drug tolerability in patients. Evidence of Notch pathway inhibition was demonstrated in peripheral blood. A surprisingly high rate of response was seen in desmoid tumors, a rare but sometimes locally aggressive sarcoma.
Original language | English (US) |
---|---|
Pages (from-to) | 7-9 |
Number of pages | 3 |
Journal | Clinical Cancer Research |
Volume | 21 |
Issue number | 1 |
DOIs | |
State | Published - Jan 1 2015 |
Externally published | Yes |
ASJC Scopus subject areas
- Oncology
- Cancer Research